Latest Europe News

Ava Risk Group expects FY2026 revenue around $29 million, below prior guidance, due to delayed orders mainly in the Middle East and North America. Despite this, sales intake exceeded revenue, underpinning a strong backlog and positive EBITDA.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Volt Resources’ Ukrainian subsidiary Zavalievsky Graphite is launching a new graphite production campaign in July 2026, supported by firm European sales contracts worth around €377,000.

Phoslock Environmental Technologies increased production significantly in the June quarter but faced a higher operating cash flow deficit and ongoing legal disputes.

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Strickland Metals has increased the inferred resource at its Copper Canyon deposit in Serbia, adding nearly 300,000 ounces of gold and enhancing the Rogozna Project's standing as one of Europe's largest undeveloped gold-copper assets.

Vulcan Energy has received the first tranche of equity funding from its €2.2 billion financing package for the Lionheart lithium and geothermal project, confirming progress aligned with its construction schedule.

Vection Technologies has secured a three-year, $7.5 million framework agreement with Switzerland’s URBANnext SA to deploy its Algho AI platform across European smart city and infrastructure markets, establishing a committed revenue floor and extending its indirect sales channel.

OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.

CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).

Datagate Innovation Limited reports steady 23% ARR growth despite customer churn and pricing pressure, while targeting a US$5 million ARR milestone to enhance its valuation over the next two years.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.